KHKay Herbrig

Kay Herbrig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kay Herbrig has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kidney Transplantation Substantially Improves Endothelial Progenitor Cell Dysfunction in Patients with End-Stage Renal Disease

    by K. Herbrig, K. Gebler, U. Oelschlaegel, F. Pistrosch, S. Foerster, A. Wagner, P. Gross, J. Passauer


  • Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells

    by K Herbrig, S Haensel, U Oelschlaegel, F Pistrosch, S Foerster, J Passauer

    Background: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality attributable to accelerated atherosclerosis and cardiovascular events. Objective: To determine the role played by endothelial progenitor cells (EPC) in the defence system against arteriosclerosis. Methods: The number and function of EPC in 13 young patients with RA with low disease activity (DAS28 3.5 (0.3)) and 13 healthy control subjects was studied. Endothelial function was investigated by agonist-induced, endothelium dependent vasodilatation measured by the forearm blood flow technique. Migratory activity and adhesion of EPC to tumour necrosis factor α (TNFα) activated mature endothelial cells and components of the extracellular matrix were tested in vitro. Putative precursor populations (CD34+, CD34+/CD133+, and CD34+/KDR+ haematopoietic stem cells) were measured by flow cytometric analysis. Results: Acetylcholine-induced, endothelium dependent vasodilatation was reduced by about 50% in patients with RA, indicating endothelial dysfunction, whereas endothelium-independent vasodilatation in response to glyceryl trinitrate was at control level. Significantly reduced numbers of EPC were found in the patients compared with controls. Migratory activity of EPC was decreased in patients with RA. Adhesion to mature endothelial cells after activation with TNFα was enhanced only in controls. The adhesion to matrix proteins and the number of putative precursor cell lineages was comparable in both groups. Conclusion: Endothelial dysfunction in patients with RA with low grade inflammation is associated with a reduced number and partial dysfunction of EPC. Further studies are needed to explore whether interventions that potentially ameliorate the number and function of EPC also improve endothelial function in these patients.


    • 1 November 2004
      • Vol. 44  (5) , 840-9

    Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis.

    by Kay Herbrig, Frank Pistrosch, Uta Oelschlaegel, Gunnar Wichmann, Andrea Wagner, Sarah Foerster, Susanne Richter, Peter Gross, Jens Passauer

    Endothelial progenitor cells (EPCs), derived from bone marrow, contribute to vessel repair and neovascularization. Because uremia is a state of endothelial dysfunction associated with high cardiovascular mortality, as well as a state of reduced hematopoiesis, we studied the number and function of EPCs in patients on long-term hemodialysis (HD) therapy. We counted the number of EPCs in 20 HD patients and 16 healthy volunteers. To assess EPC function, we measured migratory activity, adhesion to matrix proteins, and adhesion to endothelial cells. Furthermore, we measured blood levels of vascular endothelial growth factor (VEGF) and granulocyte-macrophage colony-stimulating factor, factors known to influence EPC kinetics. Circulating precursor cells (CD34+ , CD34+ /CD133+ , CD34+ /KDR+ cells) were counted by means of flow cytometric analysis. The number of EPCs in HD patients was significantly elevated compared with controls (459.7 +/- 92 versus 364.8 +/- 77.4 EPC/high-power field). However, migratory activity was markedly decreased in HD patients (47.5 +/- 27.7 versus 84.7 +/- 3.2 EPC/high-power field). EPCs of HD patients showed impaired adhesion to extracellular matrix and endothelial cells. VEGF blood levels in HD patients were 2-fold greater compared with controls. The number of circulating CD34+ and CD34+ /133+ cells was reduced in HD patients. There were no differences in total numbers of CD34+ /KDR+ cells. This study shows an elevated number, but pronounced functional impairment, of EPCs in patients on long-term HD therapy. The latter may result in limited endothelial repair, which, in turn, may contribute to endothelial dysfunction in this particular group of patients.


  • Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis

    by Kay Herbrig, Frank Pistrosch, Uta Oelschlaegel, Gunnar Wichmann, Andrea Wagner, Sarah Foerster, Susanne Richter, Peter Gross, Jens Passauer


    • 1 January 2004
      • Vol. 49

    Role of endothelial progenitor cells in cardiovascular pathology.

    by P Gross, K Herbrig

    Replacement of injured endothelial cells by bone marrow derived endothelial progenitor cells (EPC's) is a new pathway of vascular repair after ischemia. Endothelial progenitor cells contribute less than 0.01% to the peripheral venous compartment of mononuclear cells. The detection of EPC's requires a demonstration of CD 34 and VEGFR-2 (vascular endothelial growth factor receptor-2) antigenic cell membrane determinants and proof of endothelial characteristics after outgrowth and differentiation in cell culture. The most important stimuli to the mobilization and proliferation of EPC's are VEGF, GM-CSF (granulocyte-macrophage colony stimulating factor), erythropoietin, HMG-CoA-reductase inhibitors and tissue ischemia. In vivo in patients EPC's appear to contribute to endothelialization of vascular grafts, the formation of collaterals of ischemic limbs and the healing of myocardial infarcts. The role of EPC's in uremia is currently under investigation.


  • Neue Möglichkeiten der Behandlung der schweren Hyponatriämie

    by C. Palm, K. Herbrig, P. Gross

    Die Hyponatriämie stellt die häufigste Elektrolytstörung im klinischen Alltag dar und ist auf Störungen der Osmoregulation zurückzuführen. Die Hyponatriämie weist somit auf einen relativen Wasserüberschuss hin. Die Plasmaosmolalität unterliegt einer präzisen Regulierung, die über ADH, den Durst, die Flüssigkeitszufuhr und die renale Wasserausscheidung gewährleistet wird. Störungen der physiologischen Osmoregulation gehen daher im Prinzip immer auf eine Veränderung der ADH-Sekretion, des Durstmechanismus, der adäquaten Flüssigkeitszufuhr oder der renalen Wasserausscheidung zurück. Dabei ist die ADH-gesteuerte renale Wasserausscheidung meist das für die Hyponatriämie entscheidende Regelglied. Die pathologisch vermehrte ADH-Sekretion wird im klinischen Alltag vor allem bei Patienten mit fortgeschrittener Herz- oder Leberinsuffizienz beobachtet sowie bei paraneoplastischen Syndromen. In der erstgenannten Gruppe (Herz- und Leberinsuffizienz) ist das Signal für die gesteigerte ADH-Sekretion barorezeptorvermittelt und entsprechend fallen diese Patienten durch eher erhöhte Plasmakonzentrationen von Harnstoff und Kreatinin auf. Bei paraneoplastischem Syndrom besteht hingegen eine ungeregelte ADH-Sekretion aus Tumorzellen (z. B. kleinzelliges Bronchialkarzinom). Es liegen keine Kreislaufveränderungen zugrunde. Dementsprechend ist diese Form der Hyponatriämie an auffallend niedrigen Plasmakonzentrationen von Harnstoff, Kreatinin und Harnsäure, die sogar innerhalb des Normbereiches liegen können, zu erkennen. Die Symptomatik der Hyponatriämie wird im Wesentlichen von der Geschwindigkeit mit der sie sich entwickelt bestimmt (schneller Eintritt der Störung → verstärkte Symptome). Im Vordergrund stehen dabei zerebrale Symptome. In der Therapie der Hyponatriämie, bringt die Entwicklung der V2-Vasopressin-Rezeptorantagonisten neue spezifische und viel versprechende Behandlungsmöglichkeiten mit sich. Hyponatraemia is the most frequent electrolyte disturbance in clinical practice. Hyponatraemia is a disorder of the regulation of plasma osmolality and therefore represents an excess of body water. Under physiological circumstances plasma osmolality is regulated by ADH, thirst and renal water excretion. Therefore in hyponatraemia vasopressin, thirst and/or renal water excretion will have to be dysregulated to bring about the hypoosmolality. In clinical practice hyponatraemia is encountered in the advanced stages of congestive heart failure (CHF), liver cirrhosis, and volume contraction as well as in the syndrome of inappropriated antidiuretic hormone secretion (SIADH). In these disorders hyponatraemia is caused by nonosmotic vasopressin and sustained fluid intake. Two types of hyponatraemia are differentiated: a.) so-called nonosmotic related hyponatraemia (CHF, liver cirrhosis, volume contraction) and b.) the SIADH-type hyponatraemia. The low arterial blood pressure typically present in CHF, liver cirrhosis and volume contraction provides the stimulus to baroreceptor activation, resulting in an increased vasopressin secretion. In SIADH-type hyponatraemia the stimuli of nonosmotic vasopressin release are not precisely known. These may originate either from tumour cells or from the hypothalamus. Hyponatraemic patients may suffer from lethargy, difficulty to concentrate, disorientation muscular cramps, grand mal seizures, and even coma. It is important to know that these symptoms are mainly related to the rate of decrease of serum sodium concentration (rapid electrolyte disturbance → symptoms). During the last few years pharmaceutical research has uncovered novel agents that are effective oral V2 vasopressin receptor antagonists. Recently these agents have yielded promising results in the treatment of experimental and clinical hyponatraemia.